APM

Aptorum Group Limited | Cotação de Ações

Última atualização23/07/2025, 13:21:29

PreçoUS$ 1,79

Variação (dia)US$ 0,18 (11.15%)▲

Min. 52 SemanasUS$ 0,46

Máx. 52 SemanasUS$ 7,49

Capitalização de mercado--

Endereço: 17 Hanover Square, London, W1S 1BN

Telefone: 44 20 8092 9299

Funcionários: 1

Aptorum Group LimitedAPM

US$ 1,79

+ 0,1811%

23/07/2025 13:21:29

1D 7D 1M 3M 1A Tudo

Visão geral da empresa

Preço atualUS$ 1,79

Valor de mercado--

AberturaUS$ 2,10

Preço máximoUS$ 1,79

Preço mínimoUS$ 1,59

VolumeUS$ 181 mil

Fechamento anteriorUS$ 1,61

Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

Ações relacionadas

Adial Pharmaceuticals, Inc.

ADIL ▼0.01% | US$ 0,97

Hoth Therapeutics, Inc.

HOTH ▼0.14% | US$ 1,33

Lixte Biotechnology Holdings, Inc.

LIXT ▼0.13% | US$ 2,33

Alterity Therapeutics Limited

ATHE ▼0.15% | US$ 3,18

Aditxt, Inc.

ADTX ▲0.01% | US$ 0,12

Assine nossa newsletter para receber atualizações gratuitas por e-mail

Mantenha-se informado assinando nossa newsletter. Receba atualizações gratuitas por e-mail, incluindo rendimentos, novidades do mercado e insights valiosos. Estamos comprometidos em fornecer informações relevantes diretamente à sua caixa de entrada.

Fique por dentro das últimas notícias do mundo financeiro em nosso Blog

Mantenha-se atualizado com as últimas notícias financeiras em nosso Blog. Publicamos artigos informativos e análises de especialistas para fornecer insights valiosos sobre o cenário financeiro em constante evolução.

Acesse a Documentação para uma compreensão detalhada da nossa plataforma

Explore a Documentação para uma compreensão detalhada de como utilizar efetivamente nossa plataforma para análise de investimentos. Oferecemos recursos abrangentes para orientar investidores, desde iniciantes até experientes, na navegação por nossa plataforma.